Leukemic Stem Cells Make Their Own Ketones to Dodge Cell Death
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Summary
Scientists discovered that leukemic stem cells in acute myeloid leukemia generate their own ketone bodies — the same molecules produced during fasting or ketogenic diets — to protect themselves from a form of programmed cell death called ferroptosis. The key enzyme driving this process, HMGCS2, is highly active in leukemic stem cells but not in normal blood stem cells. When researchers disabled this enzyme in mouse and human leukemia models, leukemic stem cells lost their protective shield, died at higher rates, and the disease progressed more slowly. Normal blood stem cells were largely unaffected. This finding reveals an unexpected metabolic self-defense mechanism in cancer stem cells and points toward a new therapeutic strategy that could selectively eliminate leukemia-driving cells while sparing healthy tissue.
Detailed Summary
Acute myeloid leukemia (AML) remains one of the most lethal blood cancers, largely because leukemic stem cells (LSCs) resist standard therapies and drive relapse. Understanding the unique metabolic strategies LSCs use to survive is essential for developing more effective treatments.
This study, published in Cell Stem Cell, reveals that LSCs engage in autonomous ketogenesis — a metabolic pathway previously considered exclusive to liver and intestinal cells — to produce the ketone body beta-hydroxybutyrate (BHB). This process is fueled by fatty acid oxidation and governed by the rate-limiting enzyme HMGCS2, which is significantly more active in LSCs than in normal hematopoietic stem cells or AML blast cells.
The researchers found that the BHB produced through this pathway suppresses ferroptosis, a form of iron-dependent, oxidative cell death that is increasingly recognized as a cancer-relevant mechanism. Specifically, BHB limits pro-ferroptotic phospholipid remodeling by epigenetically downregulating the enzyme FADS2, which modulates lipid unsaturation. In mouse and human AML models, genetic deletion of Hmgcs2 depleted BHB, disrupted LSC self-renewal, and significantly impaired leukemia progression — all while leaving normal hematopoiesis largely intact.
The therapeutic implications are notable. Because HMGCS2 is selectively overexpressed in LSCs relative to healthy stem cells, it represents a potentially cancer-specific vulnerability. Drugs targeting HMGCS2 or downstream BHB-FADS2 signaling could selectively kill LSCs without the broad toxicity of current chemotherapy regimens.
Caveats include the reliance on abstract-only data for this summary, meaning mechanistic details and statistical rigor could not be fully evaluated. The study used both mouse and human AML models, which is encouraging, but clinical translation will require pharmacological HMGCS2 inhibitors with proven safety profiles — none of which are yet established for this indication.
Key Findings
- LSCs in AML produce their own ketone bodies (BHB) via HMGCS2-driven ketogenesis to survive.
- BHB suppresses ferroptotic cell death by epigenetically silencing FADS2, a lipid-remodeling enzyme.
- Deleting Hmgcs2 in AML models disrupts LSC function and slows leukemia progression significantly.
- Normal hematopoietic stem cells are largely spared, suggesting a cancer-specific therapeutic window.
- Ketogenesis is now established as active in non-hepatic cancer stem cells, not just liver tissue.
Methodology
The study used genetic deletion of Hmgcs2 in both mouse and human AML models to assess the role of ketogenesis in LSC survival and leukemia progression. Mechanistic analyses included measurement of BHB levels, ferroptosis markers, phospholipid profiling, and epigenetic regulation of FADS2. Normal hematopoiesis was evaluated as a comparator to assess selectivity.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; mechanistic and statistical details could not be independently verified. The study relied on genetic rather than pharmacological inhibition of HMGCS2, so clinical translatability depends on development of suitable small-molecule inhibitors. Mouse and human AML models may not fully recapitulate the heterogeneity of clinical AML.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.